Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout ...Middle East

STOCKHOLM, July 2, 2024 /PRNewswire/ -- Sobi® today announced the initiation of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SEL-212. The submission is based on the results of the DISSOLVE I and II pivotal studies. SEL-212 is an...

Hence then, the article about sobi initiates rolling biologics license application to fda for sel 212 for the potential treatment of chronic refractory gout was published today ( Tuesday 02/07/2024 - 09:25 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout )

Also on site :

• Hollywood mourns loss of beloved makeup artist Jasen Kaplan
• Suspected mountain lion attack in Colorado mountains under investigation
• Person falls to death on Boylston Street on New Year’s Eve